ABEONA THERAPEUT. DL-01 (PCJ) - Total Liabilities
Based on the latest financial reports, ABEONA THERAPEUT. DL-01 (PCJ) has total liabilities worth €60.35 Million EUR (≈ $70.56 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PCJ cash generation efficiency to assess how effectively this company generates cash.
ABEONA THERAPEUT. DL-01 - Total Liabilities Trend (2021–2025)
This chart illustrates how ABEONA THERAPEUT. DL-01's total liabilities have evolved over time, based on quarterly financial data. Check PCJ financial resilience to evaluate the company's liquid asset resilience ratio.
ABEONA THERAPEUT. DL-01 Competitors by Total Liabilities
The table below lists competitors of ABEONA THERAPEUT. DL-01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Voxel S.A.
WAR:VOX
|
Poland | zł291.06 Million |
|
Xpro India Limited
NSE:XPROINDIA
|
India | Rs-6.10 Billion |
|
Air Asia Co Ltd
TW:2630
|
Taiwan | NT$2.17 Billion |
|
Northern Ocean Ltd
OL:NOL
|
Norway | Nkr662.45 Million |
|
Vátryggingafélag Íslands hf
IC:SKAGI
|
Iceland | Ikr44.30 Billion |
|
ST.GEORGE MINING LTD
F:S0G
|
Germany | €998.48K |
|
John Marshall Bancorp Inc
NASDAQ:JMSB
|
USA | $2.07 Billion |
|
Bintang Oto Global Tbk PT
JK:BOGA
|
Indonesia | Rp343.96 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down ABEONA THERAPEUT. DL-01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ABEONA THERAPEUT. DL-01 (PCJ) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABEONA THERAPEUT. DL-01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABEONA THERAPEUT. DL-01 (2021–2025)
The table below shows the annual total liabilities of ABEONA THERAPEUT. DL-01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €60.35 Million ≈ $70.56 Million |
-7.00% |
| 2024-12-31 | €64.90 Million ≈ $75.87 Million |
+31.97% |
| 2023-12-31 | €49.18 Million ≈ $57.49 Million |
+31.30% |
| 2022-12-31 | €37.45 Million ≈ $43.79 Million |
+0.63% |
| 2021-12-31 | €37.22 Million ≈ $43.51 Million |
-- |
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more